A Phase 3 interventional study of Placebo and Pramipexole in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed at 119 sites in 15 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2014-06-09.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.
Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 6th largest by enrollment, is the only one that started in 2008, is one of 11 in phase 3, and was the 14th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 12 · Phase 4 10
First in 1998; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 511 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 224 across the 26 interventional studies. Of the 24 that completed or were terminated, 15 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 26 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
42 studies in Parkinson Disease by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 42 finished, 22 (52%) have results posted.
Among the 42 studies in Parkinson Disease by Boehringer Ingelheim, this one is the 5th largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2008, is one of 10 in phase 3, and was the 16th registered.
Boehringer Ingelheim’s Parkinson Disease studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing pramipexole in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 42 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The general aim of this study is to obtain long-term safety and tolerability data on pramipexole ER, in daily doses from 0.375mg to 4.5mg once daily (q.d), in patients who have previously completed a pramipexole double-blind study in early PD (248.524(NCT00479401) or 248.636(NCT00558025) trial).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient to receive Pramipexole ER 0.375-4.5 mg tabl form daily
Drug: Pramipexole
Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
Drug: Placebo
Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
ER 0.375-4,5 mg
Percentage of Patients With Adverse Events, Adverse Drug Reactions, Serious Adverse Events
The aim of this study was to obtain long-term safety and tolerability data on pramipexole ER, in patients who have previously completed a pramipexole double blind study in early PD (248.524 (NCT00479401) or 248.636 (NCT00558025)). Therefore these items were considered as a safety evaluation
Time frame: 80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)
Unified Parkinson's Disease Rating Scale (UPDRS) II+III Total Score: Change From Baseline
UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms
Time frame: Open Label (OL) baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)
Number of Patients With UPDRS II+III Response From OL Baseline at Week 80 (Patients From 248.524) or Week 72 (Patients From 248.636)
A response means an improvement of \>=20% from OL baseline. UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms
Time frame: OL Baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)
UPDRS I Total Score: Change From OL Baseline
UPDRS I ranging from 0 (normal) to 16 (severe), measures Mentation, Behavior and Mood
Time frame: OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)
UPDRS II Total Score: Change From OL Baseline
UPDRS II ranging from 0 (normal) to 52 (severe), measures activity of daily living.
Time frame: OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)
UPDRS III Total Score: Change From OL Baseline
UPDRS III ranging from 0 (normal) to 108 (severe) measures motor symptoms
Time frame: OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)
Response in Clinical Global Impression of Improvement (CGI-I)
Clinicians evaluation in a rating scale of 7 steps, 1 meaning very much improved to 7 meaning very much worse. For patients previously treated with Placebo, all patients with at least "much improved" were considered as responders. For patients previously treated with Pramipexole ER or Immediate Release (IR), all patients with no change to very much improved were considered as responders
Time frame: OL Baseline and week 32 (patients from 248.524) or week 24 (patients from 248.636)
Response in Patient Global Impression of Improvement (PGI-I)
Patient rated evaluation of the PD symptoms on a rating scale of 7 steps, 1 meaning very much better to 7 meaning very much worse. For patients previously treated with Placebo, all patients with at least "much better" were considered as responders. For patients previously treated with pramipexole (PPX) ER or IR, all patients with no change to very much better were considered as responders
Time frame: OL Baseline and week 32 (patients from 248.524) or week 24 (patients from 248.636)
Parkinson Fatigue Scale (PFS-16) : Change From OL Baseline
PFS-16 ranging from 16 (better perceived health status) to 80 (severe symptoms of the disease) measuring aspects of fatigue that are relevant to patients with PD.
Time frame: OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)
Number of Patients Introducing L-Dopa Medication in OL Trial
Number of patients requiring Levodopa supplementation during the study
Time frame: 80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)
L-Dopa Dose: Change From OL Baseline
Change from open-label baseline in Levodopa dose
Time frame: OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)
Pramipexole Doses Respectively After 80 Weeks Compared to Pramipexole Doses at Week 8 for Previously 248.524 Patients and After 72 Weeks Compared to Pramipexole Doses at Week 0 for Previously 248.636 Patients
Change from open-label baseline in Levodopa dose over the final 72 weeks of open-label assessment
Time frame: Week 8 and week 80 (patients from 248.524) or week 0 and week 72 (patients from 248.636)
Patient Preference Regarding Treatment Dosing
Patients were surveyed on their preference for Once Daily dosing versus Three Times Daily dosing
Time frame: 80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)
Patient Rating of Convenience of Treatment Dosing
Patients were surveyed on the convenience of Once Daily dosing versus Three Times Daily dosing
Time frame: 80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)
| Milestone | Patients From 248.524 | Patients From 248.636 |
|---|---|---|
| Started | 368 | 143 |
| Completed | 291 | 117 |
| Not completed | 77 | 26 |
| Withdrew: Adverse event | 42 | 14 |
| Withdrew: Lack of efficacy | 3 | 0 |
| Withdrew: Protocol violation | 5 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 18 | 9 |
| Withdrew: Other | 9 | 1 |
UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms
| Units of scale | Patients From 248.524 | Patients From 248.636 |
|---|---|---|
| Unified Parkinson's Disease Rating Scale (UPDRS) II+III Total Score: Change From Baseline | 2.2 ± 9.5 | 1.5 ± 7.7 |
A response means an improvement of \>=20% from OL baseline. UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms
| Patients | Patients From 248.524 | Patients From 248.636 |
|---|---|---|
| Number of Patients With UPDRS II+III Response From OL Baseline at Week 80 (Patients From 248.524) or Week 72 (Patients From 248.636) | 73 | 27 |
UPDRS I ranging from 0 (normal) to 16 (severe), measures Mentation, Behavior and Mood
| Units of scale | Patients From 248.524 | Patients From 248.636 |
|---|---|---|
| UPDRS I Total Score: Change From OL Baseline | 0.3 ± 1.0 | 0.1 ± 1.3 |
UPDRS II ranging from 0 (normal) to 52 (severe), measures activity of daily living.
| Units of scale | Patients From 248.524 | Patients From 248.636 |
|---|---|---|
| UPDRS II Total Score: Change From OL Baseline | 1.0 ± 3.2 | 0.6 ± 3.5 |
UPDRS III ranging from 0 (normal) to 108 (severe) measures motor symptoms
| Units of scale | Patients From 248.524 | Patients From 248.636 |
|---|---|---|
| UPDRS III Total Score: Change From OL Baseline | 1.1 ± 7.2 | 0.9 ± 5.6 |
Clinicians evaluation in a rating scale of 7 steps, 1 meaning very much improved to 7 meaning very much worse. For patients previously treated with Placebo, all patients with at least "much improved" were considered as responders. For patients previously treated with Pramipexole ER or Immediate Release (IR), all patients with no change to very much improved were considered as responders
| Patients | Patients From 248.524 | Patients From 248.636 |
|---|---|---|
| Response in Clinical Global Impression of Improvement (CGI-I) | 284 | 108 |
Patient rated evaluation of the PD symptoms on a rating scale of 7 steps, 1 meaning very much better to 7 meaning very much worse. For patients previously treated with Placebo, all patients with at least "much better" were considered as responders. For patients previously treated with pramipexole (PPX) ER or IR, all patients with no change to very much better were considered as responders
| Patients | Patients From 248.524 | Patients From 248.636 |
|---|---|---|
| Response in Patient Global Impression of Improvement (PGI-I) | 265 | 111 |
PFS-16 ranging from 16 (better perceived health status) to 80 (severe symptoms of the disease) measuring aspects of fatigue that are relevant to patients with PD.
| Units of scale | Patients From 248.524 | Patients From 248.636 |
|---|---|---|
| Parkinson Fatigue Scale (PFS-16) : Change From OL Baseline | 2.0 ± 12.5 | 2.2 ± 9.8 |
Number of patients requiring Levodopa supplementation during the study
| Patients | Patients From 248.524 | Patients From 248.636 |
|---|---|---|
| No | 320 | 117 |
| Yes | 47 | 21 |
Change from open-label baseline in Levodopa dose
| Patients | Patients From 248.524 | Patients From 248.636 |
|---|---|---|
| Decrease | 4 | 0 |
| Increase | 9 | 23 |
| No change | 19 | 41 |
Change from open-label baseline in Levodopa dose over the final 72 weeks of open-label assessment
| Patients | Patients From 248.524 | Patients From 248.636 |
|---|---|---|
| Decrease | 101 | 9 |
| Increase | 82 | 44 |
| No change | 156 | 73 |
The aim of this study was to obtain long-term safety and tolerability data on pramipexole ER, in patients who have previously completed a pramipexole double blind study in early PD (248.524 (NCT00479401) or 248.636 (NCT00558025)). Therefore these items were considered as a safety evaluation
| Percentage of participants | Patients From 248.524 | Patients From 248.636 |
|---|---|---|
| Percentage of Patients with Adverse Events | 84.5 | 76.2 |
| Percentage of Patients with Adverse Drug Reactions | 45.7 | 23.1 |
| Percentage of Patients with Serious Adverse Events | 14.4 | 14.7 |
Patients were surveyed on their preference for Once Daily dosing versus Three Times Daily dosing
| participants | Patients From 248.524 | Patients From 248.636 |
|---|---|---|
| Prefer Once Daily dosing | 275 | 78 |
| Prefer 3 Times Daily dosing | 9 | 1 |
| No Preference | 7 | 4 |
| Missing | 76 | 55 |
Patients were surveyed on the convenience of Once Daily dosing versus Three Times Daily dosing
| participants | Patients From 248.524 | Patients From 248.636 |
|---|---|---|
| Once Daily much more convenient | 196 | 59 |
| Once Daily more convenient | 79 | 19 |
| 3 Times Daily much more convenient | 2 | 0 |
| 3 Times Daily more convenient | 6 | 1 |
| No difference in preference | 7 | 4 |
| Missing | 77 | 55 |
Collected over Up to 80 weeks for patients from 248.524, Up to 72 weeks for patients from 248.636. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Patients From 248.524 | — | 53/368 (14.4%) | 214/368 (58.2%) |
| Patients From 248.636 | — | 21/143 (14.7%) | 62/143 (43.4%) |
| Event | Patients From 248.524 | Patients From 248.636 |
|---|---|---|
| FallInjury, poisoning and procedural complications | 3/368 | 5/143 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/368 | 3/143 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/368 | 2/143 |
| Parkinson's diseaseNervous system disorders | 2/368 | 2/143 |
| Myocardial infarctionCardiac disorders | 4/368 | 1/143 |
| AnaemiaBlood and lymphatic system disorders | 1/368 | 1/143 |
| Aortic valve incompetenceCardiac disorders | 0/368 | 1/143 |
| Atrioventricular block completeCardiac disorders | 0/368 | 1/143 |
| BradycardiaCardiac disorders | 0/368 | 1/143 |
| MalaiseGeneral disorders | 0/368 | 1/143 |
| Event | Patients From 248.524 | Patients From 248.636 |
|---|---|---|
| SomnolenceNervous system disorders | 67/368 | 10/143 |
| Oedema peripheralGeneral disorders | 45/368 | 15/143 |
| Back painMusculoskeletal and connective tissue disorders | 40/368 | 13/143 |
| NauseaGastrointestinal disorders | 37/368 | 10/143 |
| DizzinessNervous system disorders | 32/368 | 3/143 |
| NasopharyngitisInfections and infestations | 29/368 | 8/143 |
| Parkinson's diseaseNervous system disorders | 7/368 | 10/143 |
| CataractEye disorders | 25/368 | 7/143 |
| ConstipationGastrointestinal disorders | 15/368 | 9/143 |
| HallucinationPsychiatric disorders | 8/368 | 8/143 |
Treated Set, all patients randomized and received treatment
| Age, Continuous(Years) | Patients From 248.524 | Patients From 248.636 | Total |
|---|---|---|---|
| Mean | 62.2 ± 9.2 | 64.0 ± 9.0 | 62.7 ± 9.2 |
| Sex: Female, Male(Participants) | Patients From 248.524 | Patients From 248.636 | Total |
|---|---|---|---|
| Female | 164 | 62 | 226 |
| Male | 204 | 81 | 285 |
Showing the first 100 of 119 sites across 15 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2008 and a primary completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pramipexole